<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34446086</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2051-5960</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Aug</Month><Day>26</Day></PubDate></JournalIssue><Title>Acta neuropathologica communications</Title><ISOAbbreviation>Acta Neuropathol Commun</ISOAbbreviation></Journal><ArticleTitle>Blood-spinal cord barrier leakage is independent of motor neuron pathology in ALS.</ArticleTitle><Pagination><StartPage>144</StartPage><MedlinePgn>144</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">144</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40478-021-01244-0</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease involving progressive degeneration of upper and lower motor neurons. The pattern of lower motor neuron loss along the spinal cord follows the pattern of deposition of phosphorylated TDP-43 aggregates. The blood-spinal cord barrier (BSCB) restricts entry into the spinal cord parenchyma of blood components that can promote motor neuron degeneration, but in ALS there is evidence for barrier breakdown. Here we sought to quantify BSCB breakdown along the spinal cord axis, to determine whether BSCB breakdown displays the same patterning as motor neuron loss and TDP-43 proteinopathy. Cerebrospinal fluid hemoglobin was measured in living ALS patients (n&#x2009;=&#x2009;87 control, n&#x2009;=&#x2009;236 ALS) as a potential biomarker of BSCB and blood-brain barrier leakage. Cervical, thoracic, and lumbar post-mortem spinal cord tissue (n&#x2009;=&#x2009;5 control, n&#x2009;=&#x2009;13 ALS) were then immunolabelled and semi-automated imaging and analysis performed to quantify hemoglobin leakage, lower motor neuron loss, and phosphorylated TDP-43 inclusion load. Hemoglobin leakage was observed along the whole ALS spinal cord axis and was most severe in the dorsal gray and white matter in the thoracic spinal cord. In contrast, motor neuron loss and TDP-43 proteinopathy were seen at all three levels of the ALS spinal cord, with most abundant TDP-43 deposition in the anterior gray matter of the cervical and lumbar cord. Our data show that leakage of the BSCB occurs during life, but at end-stage disease the regions with most severe BSCB damage are not those where TDP-43 accumulation is most abundant. This suggests BSCB leakage and TDP-43 pathology are independent pathologies in ALS.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Waters</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Brain Research, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Swanson</LastName><ForeName>Molly E V</ForeName><Initials>MEV</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Medical Imaging, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Brain Research, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dieriks</LastName><ForeName>Birger V</ForeName><Initials>BV</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Medical Imaging, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Brain Research, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yibin B</ForeName><Initials>YB</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Brain Research, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grimsey</LastName><ForeName>Natasha L</ForeName><Initials>NL</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Brain Research, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Helen C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Medical Imaging, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Brain Research, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Clinton</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centre for Brain Research, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LabPlus, Auckland City Hospital, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waldvogel</LastName><ForeName>Henry J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Medical Imaging, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Brain Research, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faull</LastName><ForeName>Richard L M</ForeName><Initials>RLM</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Medical Imaging, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Brain Research, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Jiyan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Neurobiology, Barrow Neurological Institute, Phoenix, ARI, 85013, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowser</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Neurobiology, Barrow Neurological Institute, Phoenix, ARI, 85013, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Curtis</LastName><ForeName>Maurice A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Medical Imaging, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Brain Research, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dragunow</LastName><ForeName>Mike</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand. m.dragunow@auckland.ac.nz.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Brain Research, University of Auckland, Auckland, New Zealand. m.dragunow@auckland.ac.nz.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scotter</LastName><ForeName>Emma</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-4064-3599</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand. emma.scotter@auckland.ac.nz.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Brain Research, University of Auckland, Auckland, New Zealand. emma.scotter@auckland.ac.nz.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Biological Sciences, University of Auckland, Auckland, New Zealand. emma.scotter@auckland.ac.nz.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Acta Neuropathol Commun</MedlineTA><NlmUniqueID>101610673</NlmUniqueID><ISSNLinking>2051-5960</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006454">Hemoglobins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065634" MajorTopicYN="N">Cerebrospinal Fluid Leak</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006454" MajorTopicYN="N">Hemoglobins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Blood-spinal cord barrier</Keyword><Keyword MajorTopicYN="N">Blood&#x2013;brain barrier</Keyword><Keyword MajorTopicYN="N">Hemoglobin</Keyword><Keyword MajorTopicYN="N">Human</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword></KeywordList><CoiStatement>The authors report no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>27</Day><Hour>5</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34446086</ArticleId><ArticleId IdType="pmc">PMC8393479</ArticleId><ArticleId IdType="doi">10.1186/s40478-021-01244-0</ArticleId><ArticleId IdType="pii">10.1186/s40478-021-01244-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan MC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942&#x2013;955. doi: 10.1016/S0140-6736(10)61156-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiryaki E, Horak HA. ALS and other motor neuron diseases. Continuum (Minneap Minn) 2014;20(5):1185&#x2013;1207.</Citation><ArticleIdList><ArticleId IdType="pubmed">25299277</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravits J, Paul P, Jorg C. Focality of upper and lower motor neuron degeneration at the clinical onset of ALS. Neurology. 2007;68(19):1571&#x2013;1575. doi: 10.1212/01.wnl.0000260965.20021.47.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000260965.20021.47</ArticleId><ArticleId IdType="pubmed">17485643</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74(1):20&#x2013;38. doi: 10.1002/ana.23937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23937</ArticleId><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, et al. TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord. Acta Neuropathol. 2014;128(3):423&#x2013;437. doi: 10.1007/s00401-014-1299-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1299-6</ArticleId><ArticleId IdType="pmc">PMC4384652</ArticleId><ArticleId IdType="pubmed">24916269</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotter EL, Chen HJ, Shaw CE. TDP-43 proteinopathy and ALS: Insights into disease mechanisms and therapeutic targets. Neurotherapeutics. 2015;12(2):352&#x2013;363. doi: 10.1007/s13311-015-0338-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-015-0338-x</ArticleId><ArticleId IdType="pmc">PMC4404432</ArticleId><ArticleId IdType="pubmed">25652699</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319(5870):1668&#x2013;1672. doi: 10.1126/science.1154584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1154584</ArticleId><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Ditsworth D, et al. Mutant TDP-43 within motor neurons drives disease onset but not progression in amyotrophic lateral sclerosis. Acta Neuropathol. 2017;133(6):907&#x2013;922. doi: 10.1007/s00401-017-1698-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1698-6</ArticleId><ArticleId IdType="pmc">PMC5427168</ArticleId><ArticleId IdType="pubmed">28357566</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79(3):416&#x2013;438. doi: 10.1016/j.neuron.2013.07.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.033</ArticleId><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler EA, et al. Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Proc Natl Acad Sci U S A. 2014;111(11):E1035&#x2013;E1042. doi: 10.1073/pnas.1401595111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1401595111</ArticleId><ArticleId IdType="pmc">PMC3964055</ArticleId><ArticleId IdType="pubmed">24591593</ArticleId></ArticleIdList></Reference><Reference><Citation>Daneman R, Prat A. The blood-brain barrier. Cold Spring Harb Perspect Biol. 2015;7(1):a020412. doi: 10.1101/cshperspect.a020412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a020412</ArticleId><ArticleId IdType="pmc">PMC4292164</ArticleId><ArticleId IdType="pubmed">25561720</ArticleId></ArticleIdList></Reference><Reference><Citation>Redzic Z. Molecular biology of the blood-brain and the blood-cerebrospinal fluid barriers: similarities and differences. Fluids Barriers CNS. 2011;8(1):3. doi: 10.1186/2045-8118-8-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2045-8118-8-3</ArticleId><ArticleId IdType="pmc">PMC3045361</ArticleId><ArticleId IdType="pubmed">21349151</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt B, Sorokin L. The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction. Semin Immunopathol. 2009;31(4):497&#x2013;511. doi: 10.1007/s00281-009-0177-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-009-0177-0</ArticleId><ArticleId IdType="pubmed">19779720</ArticleId></ArticleIdList></Reference><Reference><Citation>Tumani H, Huss A, Bachhuber F. The cerebrospinal fluid and barriers - anatomic and physiologic considerations. Handb Clin Neurol. 2017;146:21&#x2013;32. doi: 10.1016/B978-0-12-804279-3.00002-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-804279-3.00002-2</ArticleId><ArticleId IdType="pubmed">29110772</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler EA, et al. Blood-spinal cord barrier pericyte reductions contribute to increased capillary permeability. J Cereb Blood Flow Metab. 2012;32(10):1841&#x2013;1852. doi: 10.1038/jcbfm.2012.113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2012.113</ArticleId><ArticleId IdType="pmc">PMC3463878</ArticleId><ArticleId IdType="pubmed">22850407</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler EA, et al. Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathol. 2013;125(1):111&#x2013;120. doi: 10.1007/s00401-012-1039-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1039-8</ArticleId><ArticleId IdType="pmc">PMC3535352</ArticleId><ArticleId IdType="pubmed">22941226</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, et al. Impaired blood-brain/spinal cord barrier in ALS patients. Brain Res. 2012;1469:114&#x2013;128. doi: 10.1016/j.brainres.2012.05.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2012.05.056</ArticleId><ArticleId IdType="pubmed">22750125</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnenfeld H, Kascsak RJ, Bartfeld H. Deposits of IgG and C3 in the spinal cord and motor cortex of ALS patients. J Neuroimmunol. 1984;6(1):51&#x2013;57. doi: 10.1016/0165-5728(84)90042-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-5728(84)90042-0</ArticleId><ArticleId IdType="pubmed">6368581</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt JI, Appel SH. IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis. Arch Neurol. 1990;47(11):1210&#x2013;1216. doi: 10.1001/archneur.1990.00530110068019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1990.00530110068019</ArticleId><ArticleId IdType="pubmed">2122877</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, et al. Proteomic analysis of cerebrospinal fluid in amyotrophic lateral sclerosis. Exp Ther Med. 2016;11(6):2095&#x2013;2106. doi: 10.3892/etm.2016.3210.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2016.3210</ArticleId><ArticleId IdType="pmc">PMC4887813</ArticleId><ArticleId IdType="pubmed">27284291</ArticleId></ArticleIdList></Reference><Reference><Citation>Saul J, et al. Global alterations to the choroid plexus blood-CSF barrier in amyotrophic lateral sclerosis. Acta Neuropathol Commun. 2020;8(1):92. doi: 10.1186/s40478-020-00968-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-00968-9</ArticleId><ArticleId IdType="pmc">PMC7318439</ArticleId><ArticleId IdType="pubmed">32586411</ArticleId></ArticleIdList></Reference><Reference><Citation>Pullen AH, et al. Passive transfer of purified IgG from patients with amyotrophic lateral sclerosis to mice results in degeneration of motor neurons accompanied by Ca2+ enhancement. Acta Neuropathol. 2004;107(1):35&#x2013;46. doi: 10.1007/s00401-003-0777-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-003-0777-z</ArticleId><ArticleId IdType="pubmed">14551798</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortes-Canteli M, et al. Fibrin deposited in the Alzheimer's disease brain promotes neuronal degeneration. Neurobiol Aging. 2015;36(2):608&#x2013;617. doi: 10.1016/j.neurobiolaging.2014.10.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.10.030</ArticleId><ArticleId IdType="pmc">PMC4315732</ArticleId><ArticleId IdType="pubmed">25475538</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua Y, et al. Brain injury after intracerebral hemorrhage: the role of thrombin and iron. Stroke. 2007;38(2 Suppl):759&#x2013;762. doi: 10.1161/01.STR.0000247868.97078.10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.STR.0000247868.97078.10</ArticleId><ArticleId IdType="pubmed">17261733</ArticleId></ArticleIdList></Reference><Reference><Citation>Regan RF, Guo Y. Toxic effect of hemoglobin on spinal cord neurons in culture. J Neurotrauma. 1998;15(8):645&#x2013;653. doi: 10.1089/neu.1998.15.645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.1998.15.645</ArticleId><ArticleId IdType="pubmed">9726263</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, et al. Prevention of motor neuron degeneration by novel iron chelators in SOD1(G93A) transgenic mice of amyotrophic lateral sclerosis. Neurodegener Dis. 2011;8(5):310&#x2013;321. doi: 10.1159/000323469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000323469</ArticleId><ArticleId IdType="pubmed">21346313</ArticleId></ArticleIdList></Reference><Reference><Citation>Wohlfart G, Swank RL. Pathology of amyotrophic lateral sclerosis: fiber analysis of the ventral roots and pyramidal tracts of the spinal cord. Arch Neurol Psychiatry. 1941;46(5):783&#x2013;799. doi: 10.1001/archneurpsyc.1941.02280230025003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurpsyc.1941.02280230025003</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S. Alterations of the blood-spinal cord barrier in sporadic amyotrophic lateral sclerosis. Neuropathology. 2015;35(6):518&#x2013;528. doi: 10.1111/neup.12221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12221</ArticleId><ArticleId IdType="pubmed">26242689</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazaki K, et al. Disruption of neurovascular unit prior to motor neuron degeneration in amyotrophic lateral sclerosis. J Neurosci Res. 2011;89(5):718&#x2013;728. doi: 10.1002/jnr.22594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.22594</ArticleId><ArticleId IdType="pubmed">21337372</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, et al. Decreased mRNA expression of tight junction proteins in lumbar spinal cords of patients with ALS. Neurology. 2009;72(18):1614&#x2013;1616. doi: 10.1212/WNL.0b013e3181a41228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181a41228</ArticleId><ArticleId IdType="pubmed">19414730</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Lee VM, Trojanowski JQ. Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat Rev Neurosci. 2011;13(1):38&#x2013;50. doi: 10.1038/nrn3121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3121</ArticleId><ArticleId IdType="pmc">PMC3285250</ArticleId><ArticleId IdType="pubmed">22127299</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, et al. Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations. Acta Neuropathol. 2013;126(6):859&#x2013;879. doi: 10.1007/s00401-013-1181-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1181-y</ArticleId><ArticleId IdType="pubmed">24096617</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravits J, et al. Implications of ALS focality: rostral-caudal distribution of lower motor neuron loss postmortem. Neurology. 2007;68(19):1576&#x2013;1582. doi: 10.1212/01.wnl.0000261045.57095.56.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000261045.57095.56</ArticleId><ArticleId IdType="pubmed">17485644</ArticleId></ArticleIdList></Reference><Reference><Citation>Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain. 1995;118:707&#x2013;719. doi: 10.1093/brain/118.3.707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/118.3.707</ArticleId><ArticleId IdType="pubmed">7600088</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanouchi T, Ohkubo T, Yokota T. Can regional spreading of amyotrophic lateral sclerosis motor symptoms be explained by prion-like propagation? J Neurol Neurosurg Psychiatry. 2012;83(7):739&#x2013;745. doi: 10.1136/jnnp-2011-301826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2011-301826</ArticleId><ArticleId IdType="pmc">PMC3368493</ArticleId><ArticleId IdType="pubmed">22544947</ArticleId></ArticleIdList></Reference><Reference><Citation>Frostell A, et al. A review of the segmental diameter of the healthy human spinal cord. Front Neurol. 2016;7:238. doi: 10.3389/fneur.2016.00238.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2016.00238</ArticleId><ArticleId IdType="pmc">PMC5179522</ArticleId><ArticleId IdType="pubmed">28066322</ArticleId></ArticleIdList></Reference><Reference><Citation>Codrich M, et al. Neuronal hemoglobin affects dopaminergic cells' response to stress. Cell Death Dis. 2017;8(1):e2538. doi: 10.1038/cddis.2016.458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2016.458</ArticleId><ArticleId IdType="pmc">PMC5386368</ArticleId><ArticleId IdType="pubmed">28055011</ArticleId></ArticleIdList></Reference><Reference><Citation>Richter F, et al. Neurons express hemoglobin alpha- and beta-chains in rat and human brains. J Comp Neurol. 2009;515(5):538&#x2013;547. doi: 10.1002/cne.22062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.22062</ArticleId><ArticleId IdType="pmc">PMC3123135</ArticleId><ArticleId IdType="pubmed">19479992</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Deza J, et al. Dipeptide repeat protein inclusions are rare in the spinal cord and almost absent from motor neurons in C9ORF72 mutant amyotrophic lateral sclerosis and are unlikely to cause their degeneration. Acta Neuropathol Commun. 2015;3(1):38. doi: 10.1186/s40478-015-0218-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-015-0218-y</ArticleId><ArticleId IdType="pmc">PMC4479315</ArticleId><ArticleId IdType="pubmed">26108573</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I, et al. TDP-43 vasculopathy in the spinal cord in sporadic amyotrophic lateral sclerosis (sALS) and frontal cortex in sALS/FTLD-TDP. J Neuropathol Exp Neurol. 2021;80:229&#x2013;239. doi: 10.1093/jnen/nlaa162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlaa162</ArticleId><ArticleId IdType="pmc">PMC7899266</ArticleId><ArticleId IdType="pubmed">33421065</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolan M, et al. Quantitative patterns of motor cortex proteinopathy across ALS genotypes. Acta Neuropathol Commun. 2020;8(1):98. doi: 10.1186/s40478-020-00961-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-00961-2</ArticleId><ArticleId IdType="pmc">PMC7331195</ArticleId><ArticleId IdType="pubmed">32616036</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC. The motor neurone disease handbook. New South Wales: Australasian Medical Company Proprietary Limited; 2007.</Citation></Reference><Reference><Citation>Eve DJ, et al. Reduction of microhemorrhages in the spinal cord of symptomatic ALS mice after intravenous human bone marrow stem cell transplantation accompanies repair of the blood-spinal cord barrier. Oncotarget. 2018;9(12):10621&#x2013;10634. doi: 10.18632/oncotarget.24360.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.24360</ArticleId><ArticleId IdType="pmc">PMC5828209</ArticleId><ArticleId IdType="pubmed">29535831</ArticleId></ArticleIdList></Reference><Reference><Citation>Rifkind JM, Mohanty JG, Nagababu E. The pathophysiology of extracellular hemoglobin associated with enhanced oxidative reactions. Front Physiol. 2014;5:500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4294139</ArticleId><ArticleId IdType="pubmed">25642190</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang SH, et al. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat Neurosci. 2013;16(5):571&#x2013;579. doi: 10.1038/nn.3357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3357</ArticleId><ArticleId IdType="pmc">PMC3637847</ArticleId><ArticleId IdType="pubmed">23542689</ArticleId></ArticleIdList></Reference><Reference><Citation>Bamm VV, et al. In vitro study of the direct effect of extracellular hemoglobin on myelin components. Biochim Biophys Acta. 2015;1852(1):92&#x2013;103. doi: 10.1016/j.bbadis.2014.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2014.10.009</ArticleId><ArticleId IdType="pubmed">25463632</ArticleId></ArticleIdList></Reference><Reference><Citation>Nation DA, et al. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med. 2019;25:270&#x2013;276. doi: 10.1038/s41591-018-0297-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0297-y</ArticleId><ArticleId IdType="pmc">PMC6367058</ArticleId><ArticleId IdType="pubmed">30643288</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Z, et al. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat Neurosci. 2008;11(4):420&#x2013;422. doi: 10.1038/nn2073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn2073</ArticleId><ArticleId IdType="pmc">PMC2895310</ArticleId><ArticleId IdType="pubmed">18344992</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomlinson BE, Irving D. The numbers of limb motor neurons in the human lumbosacral cord throughout life. J Neurol Sci. 1977;34(2):213&#x2013;219. doi: 10.1016/0022-510X(77)90069-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(77)90069-7</ArticleId><ArticleId IdType="pubmed">925710</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamura Y, et al. Lumbar motoneurons of man: I) number and diameter histogram of alpha and gamma axons of ventral root. J Neuropathol Exp Neurol. 1977;36(5):853&#x2013;860. doi: 10.1097/00005072-197709000-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-197709000-00009</ArticleId><ArticleId IdType="pubmed">894328</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell JC, et al. Wild type human TDP-43 potentiates ALS-linked mutant TDP-43 driven progressive motor and cortical neuron degeneration with pathological features of ALS. Acta Neuropathol Commun. 2015;3:36. doi: 10.1186/s40478-015-0212-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-015-0212-4</ArticleId><ArticleId IdType="pmc">PMC4479086</ArticleId><ArticleId IdType="pubmed">26108367</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotter EL, et al. Differential roles of the ubiquitin proteasome system and autophagy in the clearance of soluble and aggregated TDP-43 species. J Cell Sci. 2014;127(Pt 6):1263&#x2013;1278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3953816</ArticleId><ArticleId IdType="pubmed">24424030</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicaise C, et al. Impaired blood-brain and blood-spinal cord barriers in mutant SOD1-linked ALS rat. Brain Res. 2009;1301:152&#x2013;162. doi: 10.1016/j.brainres.2009.09.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2009.09.018</ArticleId><ArticleId IdType="pubmed">19748495</ArticleId></ArticleIdList></Reference><Reference><Citation>Jablonski MR, et al. Selective increase of two ABC drug efflux transporters at the blood-spinal cord barrier suggests induced pharmacoresistance in ALS. Neurobiol Dis. 2012;47(2):194&#x2013;200. doi: 10.1016/j.nbd.2012.03.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2012.03.040</ArticleId><ArticleId IdType="pmc">PMC3367047</ArticleId><ArticleId IdType="pubmed">22521463</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S, et al. Alterations in the blood-spinal cord barrier in TDP-43 conditional knockout mice. Neurosci Lett. 2015;598:1&#x2013;5. doi: 10.1016/j.neulet.2015.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2015.05.005</ArticleId><ArticleId IdType="pubmed">25957558</ArticleId></ArticleIdList></Reference><Reference><Citation>Ono S, et al. Collagen abnormalities in the spinal cord from patients with amyotrophic lateral sclerosis. J Neurol Sci. 1998;160(2):140&#x2013;147. doi: 10.1016/S0022-510X(98)00223-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(98)00223-8</ArticleId><ArticleId IdType="pubmed">9849796</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, et al. Endothelial and astrocytic support by human bone marrow stem cell grafts into symptomatic ALS mice towards blood-spinal cord barrier repair. Sci Rep. 2017;7(1):884. doi: 10.1038/s41598-017-00993-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-00993-0</ArticleId><ArticleId IdType="pmc">PMC5429840</ArticleId><ArticleId IdType="pubmed">28408761</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberheim NA, et al. Uniquely hominid features of adult human astrocytes. J Neurosci. 2009;29(10):3276&#x2013;3287. doi: 10.1523/JNEUROSCI.4707-08.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4707-08.2009</ArticleId><ArticleId IdType="pmc">PMC2819812</ArticleId><ArticleId IdType="pubmed">19279265</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffer D, et al. Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis. J Neurol Sci. 1996;139(Suppl):27&#x2013;33. doi: 10.1016/0022-510X(96)00073-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(96)00073-1</ArticleId><ArticleId IdType="pubmed">8899654</ArticleId></ArticleIdList></Reference><Reference><Citation>Sofroniew MV. Astrocyte barriers to neurotoxic inflammation. Nat Rev Neurosci. 2015;16(5):249&#x2013;263. doi: 10.1038/nrn3898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3898</ArticleId><ArticleId IdType="pmc">PMC5253239</ArticleId><ArticleId IdType="pubmed">25891508</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamadera M, et al. Microvascular disturbance with decreased pericyte coverage is prominent in the ventral horn of patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5&#x2013;6):393&#x2013;401. doi: 10.3109/21678421.2015.1011663.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1011663</ArticleId><ArticleId IdType="pubmed">25740316</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>